Moderna Marches Into Phase III With COVID/Flu Vaccine Combo

The US biotech major says that preliminary data show that its mRNA-1083 combination vaccine yielded antibody levels in the blood similar to or greater than two Sanofi flu vaccines and its own COVID-19 shot Spikevax.

• Source: Moderna

Moderna, Inc.'s hopes of marketing a combination vaccine against influenza and COVID-19 have moved a step further following promising early-stage results that demonstrated it was as effective as standalone jabs for the respective viruses.

Key takeaways
  • Moderna hopes mRNA-1083 can win approval in 2025
  • A COVID-19/flu vaccine combo could increase compliance and cut healthcare costs
  • Analysts seem more interested in whether the US

The US biotech has presented topline interim data from an ongoing Phase I/II trial evaluating mRNA-1083, a combination of Moderna's next-generation COVID-19 vaccine mRNA-1283 and mRNA-1010, its investigational flu vaccine

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

More from Scrip

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

AbbVie On MFN: ‘We Have To Take It Seriously’

 

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.